Marker Therapeutics (MRKR) Profit After Tax (2010 - 2026)

Marker Therapeutics (MRKR) has 17 years of Profit After Tax data on file, last reported at -$3.2 million in Q1 2026.

• Profit After Tax for Q1 2026 came in at -$3.2 million, up 28.49% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.9 million (up 14.77% YoY), and the FY2025 annual result was -$12.2 million, down 13.35% from the prior year.
• Profit After Tax fell to -$3.2 million in Q1 2026 per MRKR's latest filing, from -$1.7 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$1.7 million in Q4 2025 and troughed at -$9.9 million in Q1 2022.
• A 5-year average of -$4.4 million and a median of -$3.9 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax jumped 60.5% in 2022, then slumped 123.32% in 2023.
• A 5-year view of Profit After Tax shows it stood at -$3.9 million in 2022, then plunged by 123.32% to -$8.6 million in 2023, then soared by 55.44% to -$3.8 million in 2024, then soared by 55.62% to -$1.7 million in 2025, then plunged by 86.66% to -$3.2 million in 2026.
• Business Quant data shows MRKR's Profit After Tax at -$3.2 million in Q1 2026, -$1.7 million in Q4 2025, and -$2.0 million in Q3 2025.